http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
ZLAB INVESTOR NEWS: ROSEN, A LEADING LAW FIRM, Encourages Zai Lab Limited Investors with Losses to Inquire About Securities Class Action Investigation – ZLAB
-
Zai Lab (ZLAB) and Novocure (NVCR) Report LUNAR Phase 3 Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival
-
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lu
-
Zai Lab Limited (ZLAB) Enters Partnership and License Agreement with MediLink Therapeutics for Antibody-Drug Conjugate Program in Oncology
-
Zai Lab Announces Strategic Partnership and Global License Agreement with MediLink Therapeutics for a Next Generation Antibody-Drug Conjugate Program in Oncology
-
Zai Lab Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Zai Lab to Announce First Quarter 2023 Financial Results and Corporate Updates on May 9, 2023
-
Zai Lab to Highlight New Data from its Oncology Portfolio at 2023 AACR Annual Meeting
-
Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia
-
Zai Lab Announces Full-Year 2022 Financial Results and Recent Corporate Updates
-
Zai Lab Announces Participation in March Investor Conferences
-
Zai Lab to Present Two New Phase 3 Analyses for Niraparib in Ovarian Cancer at the 2023 ESMO Gynaecological Cancers Congress
-
Zai Lab Limited (ZLAB) Announces NDA Acceptance of Sulbactam-Durlobactam
-
Zai Lab Announces NDA Acceptance of Sulbactam-Durlobactam (SUL-DUR) for Infections Caused by Acinetobacter baumannii in China by the NMPA
-
Zai Lab to Announce Full-Year Financial Results and Corporate Updates on March 1, 2023
-
Zai Lab Announces Participation in February Investor Conferences
-
Zai Lab Limited (ZLAB) Announces NDA for Sulbactam-Durlobactam (SUL-DUR) Granted Priority Review by China’s NMPA
-
Zai Lab Announces NDA for Sulbactam-Durlobactam (SUL-DUR) Granted Priority Review by China’s NMPA
-
Zai Lab Limited (ZLAB) Announces Inclusion of QINLOCK and NUZYRA in China’s National Reimbursement Drug List
-
Zai Lab Announces Inclusion of QINLOCK® (ripretinib) and NUZYRA® (omadacycline) in China’s National Reimbursement Drug List
-
Zai Lab Limited (ZLAB) Appoints Michel Vounatsos To Its Board
-
Zai Lab Appoints Michel Vounatsos To Its Board of Directors
-
Zai Lab Limited (ZLAB) and Novocure (NVCR) Announce LUNAR Study Met Primary Overall Survival Endpoint
-
Zai Lab and Novocure Announce Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint
-
Zai Lab Announces the Appointment of Dr. Rafael G. Amado as President, Head of Global Oncology Research and Development
-
Zai Lab Announces Participation in January Investor Conferences
-
Zai Lab Limited (ZLAB) Reports Interim Overall Survival Data for ZEJULA
-
Zai Lab Presents Interim Overall Survival Data for ZEJULA® (niraparib) from the NORA Phase 3 Study at the ESMO Virtual Plenary
-
Zai Lab Partner Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
-
Zai Lab Announces Third Quarter 2022 Financial Results and Corporate Updates
-
Zai Lab to Present New Oncology Research at 2022 Society for Immunotherapy of Cancer Annual Meeting
-
Zai Lab Announces the Appointment of Dr. Peter Huang as Chief Scientific Officer
-
Zai Lab Announces Participation in November Investor Conferences
-
Zai Lab to Announce Third Quarter 2022 Financial Results on November 9, 2022
-
Zai Lab Launches its first Trust Report
-
Zai Lab Limited (ZLAB) and Seagen (SGEN) Enter Collaboration and License Agreement for TIVDAK
-
Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv)
-
Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv)
-
Zai Lab to Present Analysis of the Impact of Timing for ZEJULA® (niraparib) Maintenance Treatment in Newly Diagnosed Advanced Ovarian Cancer at the 2022 International Gynecologic Cancer Society Meeti
-
Zai Lab Announces Participation in September Investor Conferences
-
Zai Lab Announces Second Quarter 2022 Financial Results and Corporate Updates
-
Zai Lab Limited (ZLAB) Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia
-
Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia
-
Zai Lab to Announce Second Quarter 2022 Financial Results on August 9, 2022
-
Zai Lab Announces Inclusion of its Ordinary Shares in Two Stock Connect Programs
-
Zai Lab Limited (ZLAB) Announces Acceptance by China’s NMPA of the BLA for Efgartigimod for Patients with Generalized Myasthenia Gravis
-
Zai Lab Announces Acceptance by China’s NMPA of the BLA for Efgartigimod for Patients with Generalized Myasthenia Gravis
-
Zai Lab Limited (ZLAB) Announces Primary Listing on the Main Board of The Stock Exchange of Hong Kong Limited
-
Zai Lab Announces Primary Listing on the Main Board of The Stock Exchange of Hong Kong Limited
-
Zai Lab (ZLAB) Announces Breakthrough Therapy Designations Granted for Repotrectinib in China
